IP Library Patent Application 16060805
Patent Application
App. No. 16/060,805

LACTOBACILLUS CASEI FOR TREATING OBESITY AND ASSOCIATED METABOLIC DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/060,805
Abstract

The strain Lactobacillus casei AH077 (NCIMB12019) produces a polysaccharide and increases energy excretion. The strain acts to block fat absorption and is used in the prevention or treatment of obesity and obesity-related metabolic syndrome.

Claims (21)

1 - 26 . (canceled)

27 . A strain of Lactobacillus casei AH077 deposited with the NCIMB under accession number 42019.

28 . The strain as claimed in claim 27 in the form of viable cells.

29 . The strain as claimed in claim 27 in the form of non-viable cells.

30 . A formulation which comprises a strain of Lactobacillus casei AH077 deposited with the NCIMB under accession number 42019.

31 . The formulation as claimed in claim 29 which further comprises a probiotic material.

32 . The formulation as claimed in claim 29 which further comprises a prebiotic material.

33 . The formulation as claimed in claim 29 further comprising an ingestible carrier.

34 . The formulation as claimed in claim 29 wherein the ingestible carrier comprises a pharmaceutically acceptable carrier chosen from a capsule, a tablet, or a powder.

35 . The formulation as claimed in claim 29 wherein the ingestible carrier comprises a food product chosen from acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings, or beverages.

36 . The formulation as claimed in claim 29 which further comprises at least one of a protein or a peptide rich in glutamine/glutamate, a lipid, a carbohydrate, a vitamin, a mineral, a trace element, or a combination thereof.

37 . The formulation as claimed in claim 29 wherein the strain is present in an amount of more than 10 6 cfu per gram of the formulation.

38 . The formulation as claimed in claim 29 which further comprises one or more of an adjuvant, a bacterial component, a drug entity, or a biological compound.

39 . A freeze dried composition comprising the strain of Lactobacillus casei AH077 of claim 27 .

40 . A foodstuff comprising the strain of Lactobacillus casei AH077 of claim 27 .

41 . A medicament comprising the strain of Lactobacillus casei AH077 of claim 27 .

42 . A capsule comprising the strain of Lactobacillus casei AH077 of claim 27 .

43 . A method for preventing or treating a health condition, comprising administering a composition comprising a strain of Lactobacillus casei AH077 deposited with the NCIMB under accession number 42019 to a subject in need thereof.

44 . The method of claim 43 , wherein the method blocks fat absorption by the patient.

45 . The method of claim 43 , wherein the health condition includes obesity, obesity-related metabolic syndrome, or both.

46 . The method of claim 43 , wherein the health condition is non-alcoholic fatty liver disease (NAFLD).

Assignments (2)
CHANGE OF NAME Recorded Jan 10, 2020
From: ALIMENTARY HEALTH LIMITED
To: PRECISIONBIOTICS GROUP LIMITED
Reel/Frame 051480/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2018
From: KIELY, BARRY; MURPHY, EILEEN FRANCES; HEALY, SELENA
To: ALIMENTARY HEALTH LIMITED
Reel/Frame 046958/0639 →